Condition Directory

Breast Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Breast Cancer. Browse Breast Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced November 7, 2026 Report an issue

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

7084

Shown on this page

Current sort

How Breast Cancer studies are organized in the registry

Breast cancer listings are usually subtype-specific: receptor status appears directly in titles and condition fields, so subtype terms narrow results far better than stage words alone. Many studies also restrict to either early-stage or metastatic settings, which is visible in the title or eligibility section of the official record.

Terms that often appear in related listings

triple-negative HER2-positive hormone receptor-positive metastatic breast cancer

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 649–660 of 7,084 matching trials for Breast Cancer.

Live ClinicalTrials.gov results.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Breast Cancer
Interventions: Novel probiotic, Placebo; Biological · Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Breast Carcinoma
Interventions: Electronic Health Record Review, Medical Device Usage and Evaluation, Meditation Therapy, Survey Administration; Other · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Solid Tumor, Adult
Interventions: Tumor Biopsy; Procedure
Lead sponsor: TScan Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Los Angeles, California • New Orleans, Louisiana • Morristown, New Jersey + 1 more

Conditions: Breast Cancer, Breast Cancer Female, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Mild Depression, Moderate Depression
Interventions: MBCT; Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 65 Years and older · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: HER2-positive Breast Cancer
Interventions: Dendritic Cell (DC1) Vaccine, Trastuzumab, Pepinemab, T-Cell therapy; Biological · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Breast Cancer
Interventions: Surveys, Video; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer Female
Interventions: Presentation of a personal breast cancer risk estimate; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 39 Years to 74 Years · Female only
Enrollment: 781 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma, Invasive Breast Carcinoma, Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Blood Sample, Bone Scan, Computed Tomography, Entinostat, Ipilimumab, Nivolumab, Pharmacogenomic Study, Pharmacological Study, Positron Emission Tomography; Procedure · Other · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 5
States / cities: Duarte, California • New Haven, Connecticut • Baltimore, Maryland + 1 more

Conditions: Breast Cancer
Interventions: contrast enhanced mammography, Iodinated Contrast Media (ICM); Device · Drug
Lead sponsor: Margarita Louise Zuley; Other
Eligibility: 30 Years and older · Female only
Enrollment: 2,089 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Metastatic Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Breast Cancer, Locally Advanced Breast Cancer
Interventions: Palazestrant, Ribociclib, Alpelisib, Everolimus, Atirmociclib; Drug
Lead sponsor: Olema Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 14
States / cities: Gilbert, Arizona • San Francisco, California • Aurora, Colorado + 11 more

Conditions: Triple Negative Breast Cancer, HER2-positive Breast Cancer, Hormone Receptor-positive Breast Cancer
Interventions: Magnetic Resonance Imaging; Diagnostic Test
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Clearwater, Florida • Tampa, Florida

Conditions: Leptomeningeal Disease, Triple Negative Breast Cancer, HER2-positive Breast Cancer
Interventions: Dendritic Cell Vaccine; Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

About this Breast Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Breast Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Breast Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Breast Cancer clinical trials

How Breast Cancer studies are organized in the registry

Filter and sort this condition

Live official records

Study to Investigate Efficacy of a Novel Probiotic on the Bacteriome and Mycobiome of Breast Cancer

MUSE-S Headband System for Improving Anxiety and Insomnia Among Breast Cancer Survivors

A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.

Abbreviated MBCT for Depression in Older Black or African American Breast Cancer Survivors

Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer

Everyday Exposures: How Chemicals and Weight Impact Breast Cancer Risk

Understanding and Addressing Rejection of Personalized Breast Cancer Risk Information: Administrative Supplement Study

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

Study of Screening Brain MRIs in Stage IV Breast Cancer

A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)

About this Breast Cancer clinical trials directory page